Cargando…

Risk Factors for Mortality of Inpatients with Pseudomonas aeruginosa Bacteremia in China: Impact of Resistance Profile in the Mortality

PURPOSE: Pseudomonas aeruginosa bacteremia presents a severe challenge to hospitalized patients. However, to date, the risk factors for mortality among inpatients with P. aeruginosa bacteremia in China remain unclear. PATIENTS AND METHODS: This retrospective multicenter study was performed to analyz...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yulin, Li, Yi, Zeng, Ji, Chang, Yanzi, Han, Shouhua, Zhao, Jiankang, Fan, Yanyan, Xiong, Zhujia, Zou, Xiaohui, Wang, Chunlei, Li, Binbin, Li, Haibo, Han, Jiajing, Liu, Xinmeng, Xia, Yudi, Lu, Binghuai, Cao, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7669529/
https://www.ncbi.nlm.nih.gov/pubmed/33209041
http://dx.doi.org/10.2147/IDR.S268744
Descripción
Sumario:PURPOSE: Pseudomonas aeruginosa bacteremia presents a severe challenge to hospitalized patients. However, to date, the risk factors for mortality among inpatients with P. aeruginosa bacteremia in China remain unclear. PATIENTS AND METHODS: This retrospective multicenter study was performed to analyze 215 patients with culture-confirmed P. aeruginosa bacteremia in five healthcare centers in China during the years 2012–2019. RESULTS: Of 215 patients with P. aeruginosa bacteremia, 61 (28.4%) died during the study period. Logistic multivariable analysis revealed that cardiovascular disease (OR=3.978, P=0.001), blood transfusion (OR=5.855, P<0.001) and carbapenem-resistant P. aeruginosa (CRPA) phenotype (OR=4.485, P=0.038) constituted the independent risk factors of mortality. Furthermore, both CRPA and multidrug-resistant P. aeruginosa (MDRPA) phenotypes were found to be significantly associated with 5-day mortality (Log-rank, P<0.05). CONCLUSION: This study revealed a high mortality rate amongst hospitalized patients with P. aeruginosa bacteremia, and those with cardiovascular diseases, CRPA and MDRPA phenotypes, should be highlighted and given appropriate management in China.